Fractyl Health FY2029 EPS Forecast Lifted by HC Wainwright

Key Points

• HC Wainwright raised its FY2029 EPS estimate for Fractyl to $0.37 (from $0.31), maintained a Buy rating with an $8 target, and projects FY2030 EPS of $0.94.
• Fractyl beat Q4 estimates with EPS of $0.15 versus a consensus loss, prompting a sharp share rally (intraday/after‑hours moves reported ~16–21%) and elevated trading volume.
• Despite the beat, consensus still models a full‑year loss (‑$1.61), the stock trades below key moving averages, the average analyst view is Hold, and liquidity/cash‑runway and clinical execution remain key risks.

Fractyl Health, Inc. (NASDAQ:GUTS - Free Report) - Investment analysts at HC Wainwright upped their FY2029 earnings per share (EPS) estimates for shares of Fractyl Health in a report issued on Wednesday, March 25th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $0.37 per share for the year, up from their prior estimate of $0.31. HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Fractyl Health's current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Fractyl Health's FY2030 earnings at $0.94 EPS.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 24th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.34.

GUTS has been the subject of a number of other reports. Morgan Stanley downgraded Fractyl Health from an "overweight" rating to an "equal weight" rating and lowered their price objective for the stock from $8.00 to $2.00 in a research note on Thursday, January 29th. Canaccord Genuity Group reiterated a "buy" rating and set a $8.00 price objective on shares of Fractyl Health in a research note on Friday, December 19th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Fractyl Health in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Fractyl Health presently has an average rating of "Hold" and an average target price of $5.40.

Fractyl Health Stock Up 16.2%

GUTS opened at $0.50 on Thursday. The company's 50-day moving average price is $0.76 and its 200 day moving average price is $1.29. The firm has a market cap of $68.52 million, a price-to-earnings ratio of -0.27 and a beta of 1.51. Fractyl Health has a fifty-two week low of $0.38 and a fifty-two week high of $3.03.

Institutional Investors Weigh In On Fractyl Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GUTS. Jane Street Group LLC purchased a new stake in shares of Fractyl Health during the second quarter worth $31,000. FNY Investment Advisers LLC acquired a new position in shares of Fractyl Health during the 3rd quarter valued at about $31,000. Scientech Research LLC acquired a new position in Fractyl Health during the third quarter valued at approximately $49,000. Prelude Capital Management LLC bought a new position in Fractyl Health in the 3rd quarter worth $55,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in shares of Fractyl Health in the third quarter worth about $56,000.

Key Headlines Impacting Fractyl Health

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: Q4 results and EPS beat — Fractyl reported Q4 EPS of $0.15, topping the consensus loss estimate and surprising investors; management also released a formal press release with the fourth‑quarter and full‑year 2025 results. Fractyl press release
• Positive Sentiment: Clinical/program progress highlighted — Management emphasized Revita program updates in its shareholder materials and investor commentary, which supports long‑term company value if development milestones continue. Revita progress note
• Positive Sentiment: After‑hours jump and elevated volume — News coverage (MSN) notes a ~21% after‑hours move following the release, and intraday volume ran above average, signaling strong short‑term interest and trade activity. MSN after‑hours coverage
• Positive Sentiment: Short‑interest reduction reported earlier in March — Data showed a sizable drop in reported short interest to ~5.8% of float as of March 13, which can reduce downward pressure and support upside on positive news. (Market data entries)
• Neutral Sentiment: Earnings call transcript — The full Q4 2025 earnings call provides detailed commentary on cash runway, costs and strategic priorities; investors will parse guidance and cadence for future milestones. Earnings call transcript
• Neutral Sentiment: Analyst/coverage summaries — Yahoo and other outlets summarized the quarter and noted financial challenges; the tone is mixed—beat this quarter but still operational/financial questions remain. Yahoo summary
• Negative Sentiment: Ongoing financial and volatility risks — Despite the EPS beat, Wall‑Street consensus still models negative EPS for the fiscal year and the stock trades well below its 50‑ and 200‑day averages; liquidity, cash runway and execution on Revita remain key risk factors for the share price.
• Negative Sentiment: Conflicting short‑interest data — Several data feeds show inconsistent/erroneous short‑interest figures (zero/NaN entries), increasing uncertainty about true short positioning and potential for volatile squeezes or covering spikes that can exaggerate moves in either direction.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company's lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.